European Animation Industry Report 2017: Focus on Strategies, Trends and Opportunities
Jan 17, 2017 12:56 pm UTC| Business
Dublin, Jan. 17, 2017 -- Research and Markets has announced the addition of the "European Animation Industry 2017: Strategies, Trends and Opportunities" report to their offering. ...
Jan 17, 2017 12:56 pm UTC| Business
Dublin, Jan. 17, 2017 -- Research and Markets has announced the addition of the "Asian Animation Industry 2017: Strategies, Trends and Opportunities" report to their offering. The...
Abeona Therapeutics to Present at Phacilitate Cell & Gene Therapy World 2017
Jan 17, 2017 12:53 pm UTC| Business
NEW YORK andCLEVELAND, Jan. 17, 2017 -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced...
Jan 17, 2017 12:49 pm UTC| Business
Dublin, Jan. 17, 2017 -- Research and Markets has announced the addition of the "Flavonoids Market Size Trend Analysis By Product, By Application, By Region And Segment Forecasts, 2014 - 2025" report...
Tuesday Morning Corporation Announces Executive Appointments
Jan 17, 2017 12:30 pm UTC| Business
DALLAS, Jan. 17, 2017 -- Tuesday Morning Corporation (Nasdaq:TUES), a leading off-price retailer with over 720 stores across the United States, today announced two executive appointments that reflect the Company’s...
National Holdings Corporation Establishes Distribution Date for Warrant Dividend
Jan 17, 2017 12:30 pm UTC| Business
NEW YORK, Jan. 17, 2017 -- National Holdings Corporation (NASDAQ:NHLD) (“National Holdings” or the “Company”), a full-service investment banking and asset management firm, has announced that it has established January...
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
Jan 17, 2017 12:30 pm UTC| Business
LA JOLLA, Calif., Jan. 17, 2017 -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 2 clinical trial of tipifarnib in...